Tratamento de síndrome de SAPHO com ácido zoledrónico: reporte de caso
Barra lateral de artigos
Como Citar
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
##plugins.themes.bootstrap3.displayStats.downloads##
Societal impact
Conteúdo do artigo principal
Resumo
A síndrome SAPHO (sinovitis, acne, pustuloses, hiperosteoses, osteítes) é uma condição crônica e inflamatória com manifestações cutâneas e ósteo-articulares. Seu etiologia não é clara, ainda que se considerou uma possível associação com as espondiloartritis. Diferentes tratamentos com esteroides e medicamentos antiinflamatórios são utilizados nesta patologia, com resposta variável. Os bisfosfonatos são uma das novas modalidades no tratamento da síndrome de SAPHO, graças a suas propriedades anti-osteoclásticas e anti-inflamatórias. Reporta-se o caso de um paciente com SAPHO tratado com ácido zoledrónico com sucesso.
Detalhes do artigo
Referências
Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A. Acne-pustulosis-hyperostosisosteitis syndrome of a national survey: 85 cases. Rev Rheum Mal Osteoartic. 1987;54:187–196.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. HORIZON Pivotal Fracture Trial.Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. HORIZON Recurrent Fracture Trial Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
Davis JC, Huang F, Maksymowych W. New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. Rheum Dis Clin N Am. 2003;29:481–494.
Soubrier M, Dubost JJ, Ristori JM, Sauvezie B, Bussiere JL. Pamidronate in the treatment of diffuse sclerosing osteomyelitis of the mandible. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2001;92:637–640.
Guignard S, Job-Deslandre C, Sayag-Boukris V, Kahan A. Pamidronate treatment in SAPHO syndrome. Joint Bone Spine.2002;69:392–396.
Kopterides P, Pikazis D, Koufos C. Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum.2004;50:2970-2973.
Giedion A, Holthusen W, Masel LF, Vischer D. Subacute and chronic “symmetrical” osteomyelitis. Ann Radiol (Paris).1972;15:329–342.
Earwaker JW, Cotten A. SAPHO: syndrome or concept? Imaging findings. Skeletal Radiol. 2003;32:311–327.
Szanto E, Linse O. Arthropathy associated with palmoplantar pustulosis. Clin Rheumatol. 1991;10:130- 135.
Tagaki M, Oda J, Tsuzuki N, Sonozaki H. Palmoplantar pustulotic arthro-osteitis of the peripheral joints with no sternocostoclavicular lesions. Ann Rheum Dis.1992; 51:558-560.
Self SJ, Montes LF. Follicular occlusion triad. South Med J. 1970;63:156-160.
Taccari E, Spadaro A, Riccieri V, Guerrisi R, Guerrisi V, Zoppini A. Sternoclavicular joint disease in psoriatic arthritis. Ann Rheum Dis. 1992;51:372-374.
Rojas A, Rondón Herrera F, Restrepo Suarez JF. Síndrome SAPHO. Rev Col Reumatol. 2002;9:56-61.
Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin Rheumatol.1994;8: 333–362.
Serushan M, Spencer PL, Yeh WLS, Kaminski M. Osteomyelitis of cervical spine from Propionibacterium acnes. Arthritis Rheum.1982;25:346-348.
Gerster JC, Lagier R, Livio JJ. Propionibacterium acnes in spondylitis with palmoplantar pustulosis. Ann Rheum Dis.1990;49:337-339.
Maugars Y, Berthelot JM, Ducloux JM, Prost A. SAPHO syndrome: a follow-up study of 19 cases with special emphasis on enthesis involvement. J Rheumatol. 1995;22:2135-2141.
Kahn MF. Why the “SAPHO” syndrome? J Rheumatol.1995;22:2017-2019.
Reith JD, Bauer TW, Schils JP. Osseous manifestations of SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. Am J Surg Pathol.1996;20: 1368- 1377.
Pauli SL, Kokko ML, Suhonen R. Acne fulminans with bone lesions. Acta Derm Venereol.1988;68:351-355.
Brandt J, Marzo-Ortega H, Emery P. Ankylosing spondylitis: new treatment modalities. Best Pract Res Clin Rheumatol. 2006;20:559-570.
Marshall H, Bromilow J, Thomas AL, Arden NK. Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology. 2002;41:231–233.
Courtney PA, Hosking DJ, Fairbain KJ, Deighton CM. Treatment of SAPHO with pamidronate. Rheumatology. 2002;41:1196–1198.
Kerrison C, Davidson JE, Cleary AG, Beresford MW. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology.2004;43:1246–1251.
Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with Pamidronate: an open- label study of 10 patients. Rheumatology. 2004;43:658-661.
Ichikawa J, Sato E, Haro H, Ando T, Maekawa S, Hamada Y. Successful treatment of SAPHO syndrome with an oral bisphosphonate. Rheumatol Int.2009;29:713–715.
Kopterides P, Pikazis D, Koufos C. Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum. 2004;50:2970-2973.